Immuneering Corp
Immuneering Corp is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 4, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.
Cash runway is approximately 6.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 4, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| June 15, 2028 | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Trial Milestone | Phase 3 |
Track IMRX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open IMRX in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 5, 2026 | Quarterly results filed (8-K) | Earnings | — |
| June 15, 2026 | 8-K filed: Leadership change | Corporate | — |
| June 15, 2026 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | Trial Milestone | Phase 1/Phase 2 |
| June 1, 2026 | 8-K filed: Other event | Filing | — |
| May 15, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 6, 2026 | Quarterly results filed (8-K) | Earnings | — |
| January 7, 2026 | 8-K filed: Other event | Filing | — |
| November 12, 2025 | Quarterly results filed (8-K) | Earnings | — |
| September 25, 2025 | 8-K filed: Material agreement, Other event | Corporate | — |
| September 24, 2025 | 8-K filed: Material agreement, Other event | Corporate | — |
| August 25, 2025 | 8-K filed: Material agreement, Other event | Corporate | — |
| August 13, 2025 | Quarterly results filed (8-K) | Earnings | — |
| June 17, 2025 | 8-K filed: Other event | Filing | — |
| May 5, 2025 | Quarterly results filed (8-K) | Earnings | — |
| April 30, 2025 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Trial Milestone | Phase 1/Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.